Rna Diagnostics Inc. appoints
Dr. Jeremy Bridge-Cook President and CEO

Dr. Jeremy Bridge-Cook

Dr. Ken Pritzker, on behalf of the Board of Directors of Rna Diagnostics Inc., is pleased to announce the appointment of Dr. Jeremy Bridge-Cook to the position of President and Chief Executive Officer of Rna Diagnostics Inc. Dr. Bridge-Cook is a highly accomplished In Vitro Diagnostics (IVD) executive with  comprehensive experience developing and launching innovative IVD products onto global markets. Prior to assuming the President and CEO role at Rna Diagnostics, Dr. Bridge-Cook was engaged for 16 years in progressively senior business development, research and development and general management roles at Tm Bioscience (TMB) and Luminex Corporation, which acquired TMB in 2007. Dr. Bridge-Cook was a corporate officer and Senior Vice President of R&D at Luminex, a NASDAQ listed corporation that develops, manufacturers and markets IVD and biological testing technologies for the clinical diagnostic and life science industries. Dr. Bridge-Cook was instrumental in delivering new molecular diagnostic systems and assays from inception to successful commercial launch. Dr. Bridge-Cook obtained a B.Sc., Biology from McMaster University and a Ph.D., Immunology from University of Toronto.

“Jeremy brings an exceptional combination of business, scientific skills and IVD industry experience to his role as President and CEO of Rna Diagnostics. His extensive IVD industry experience is directly pertinent to the commercialization of the RNA Disruption Assay™ (RDA™) technology and the objective of delivering RDA services to cancer centres around the world” says Dr. Ken Pritzker.

Dr. Pritzker, Co-Founder and current President and CEO of Rna Diagnostics, will continue to be part of the executive leadership team. He will assume the role of Chief Innovation Officer and will continue as a member of the Board of Directors of Rna Diagnostics.

“I am excited about assuming the role of President and CEO of Rna Diagnostics and leading the commercialization of the RNA Disruption Assay™ (RDA™). RDA™ has tremendous potential to become a standard of care in chemotherapy management and to help improve the lives of cancer patients worldwide,“ says Dr. Bridge-Cook.